[Response to inhaled granulocyte-macrophage colony-stimulating factor in a patient with alveolar proteinosis].

Abstract

Pulmonary alveolar proteinosis is a rare disease characterized by the accumulation of lipoproteinaceous material derived from alveolar surfactant in the alveoli, with a consequent deterioration in gas exchange. Pathogenesis is related to impaired phagocytic function of alveolar macrophages. In recent years, a new treatment for pulmonary alveolar proteinosis-consisting of subcutaneous administration of granulocyte-macrophage colony-stimulating factor (GM-CSF)-has become available. The commonly accepted treatment, and the one to have shown greatest efficacy in pulmonary alveolar proteinosis, is whole lung lavage. Instead of subcutaneous administration, GM-CSF can also be inhaled as an aerosol. This route of administration of GM-CSF is safe and effective in the treatment of pulmonary alveolar proteinosis and represents an alternative to subcutaneous administration or whole lung lavage. We present a patient with pulmonary alveolar proteinosis who was treated with inhaled GM-CSF and describe her clinical and functional outcome after 1 year of treatment.

• Authors: José Antonio Rodríguez Portal, Eulogio Rodríguez Becerra, Antonio Sánchez Garrido
• Journal: Archivos de bronconeumologia (Arch Bronconeumol) Vol. 45 Issue 3 Pg. 150-2 (Mar 2009) ISSN: 0300-2896 [Print] Spain
• Vernacular Title: Proteinosis alveolar. Respuesta al tratamiento con factor estimulante de colonias de granulocitos y macrófagos por vía inhalada.
• PMID: 19286115 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Administration, Inhalation
• Adult
• Female
• Granulocyte-Macrophage Colony-Stimulating Factor (administration & dosage)
• Humans
• Pulmonary Alveolar Proteinosis (drug therapy)
• Time Factors